GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: LY-3303560 | LY3303560
                                 
                                                         
                            Compound class: 
                                                            Antibody
                                 
                                
                                    
                                        Comment: LY3303560 is a monoclonal antibody that selectively targets tau protein aggregates [1]. It is being developed by Eli Lilly for potential to treat Alzheimer's disease. The primary epitope for LY3303560 is located in the N-terminal region of tau.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
| Bioactivity Comments | 
| LY3303560 binding affinity (KD) for tau monomer is 235 nM which is approximately 100-fold lower than its affinity for soluble tau aggregate [1]. LY3303560 demonstrated acceptable pharmacokinetic properties in rat and monkey. | 
| Other ligands which bind to or alter the activity of this ligand | ||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||
                                                                    
                                                                     
  | 
                                                            ||||||||||||||||||||||||||||||||||||||||||||||